CL2020002294A1 - Uso de un anticuerpo anti–p–selectina - Google Patents
Uso de un anticuerpo anti–p–selectinaInfo
- Publication number
- CL2020002294A1 CL2020002294A1 CL2020002294A CL2020002294A CL2020002294A1 CL 2020002294 A1 CL2020002294 A1 CL 2020002294A1 CL 2020002294 A CL2020002294 A CL 2020002294A CL 2020002294 A CL2020002294 A CL 2020002294A CL 2020002294 A1 CL2020002294 A1 CL 2020002294A1
- Authority
- CL
- Chile
- Prior art keywords
- selectin antibody
- binding fragment
- relates
- selectin
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La invención se refiere al uso de un anticuerpo anti–P–selectina o un fragmento de unión al mismo, adecuadamente crizanlizumab o un fragmento de unión al mismo en el tratamiento de la mielofibrosis (MF). La invención también se refiere a una combinación farmacéutica que comprende a) un anticuerpo anti–P–selectina y b) al menos otro agente terapéutico, preferiblemente ruxolitinib o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640117P | 2018-03-08 | 2018-03-08 | |
| US201862640113P | 2018-03-08 | 2018-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002294A1 true CL2020002294A1 (es) | 2021-03-05 |
Family
ID=66041608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002294A CL2020002294A1 (es) | 2018-03-08 | 2020-09-04 | Uso de un anticuerpo anti–p–selectina |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210002374A1 (es) |
| EP (1) | EP3762424A1 (es) |
| JP (2) | JP2021515027A (es) |
| KR (1) | KR20210003086A (es) |
| CN (2) | CN112041344A (es) |
| AU (1) | AU2019229885A1 (es) |
| BR (1) | BR112020018135A2 (es) |
| CA (1) | CA3092931A1 (es) |
| CL (1) | CL2020002294A1 (es) |
| IL (1) | IL276937A (es) |
| MX (1) | MX2020009305A (es) |
| RU (1) | RU2020132460A (es) |
| WO (1) | WO2019171326A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021053490A1 (en) * | 2019-09-16 | 2021-03-25 | Novartis Ag | Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis |
| TWI893018B (zh) * | 2019-10-30 | 2025-08-11 | 瑞士商諾華公司 | 抗體配製物 |
| US12290565B2 (en) * | 2021-11-17 | 2025-05-06 | Altrubio Inc. | Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0642356T3 (da) | 1992-05-05 | 2003-08-04 | Aeres Biomedical Ltd | Antistoffer mod P-selectin og deres anvendelser |
| EP0804235A4 (en) | 1993-05-04 | 2001-09-19 | Aeres Biomedical Ltd | ANTIBODIES AGAINST P-SELECTIN AND THEIR USE |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| HUE041957T2 (hu) | 2006-12-01 | 2019-06-28 | Novartis Ag | Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| EP2654781B1 (en) | 2010-12-21 | 2018-01-24 | Selexys Pharmaceuticals Corporation | Anti-p-selectin antibodies and methods of their use and identification |
| HRP20250965T1 (hr) | 2012-06-15 | 2025-10-10 | Sun Pharmaceutical Industries, Inc. | Deuterirani derivati ruksolitiniba |
| WO2017218960A1 (en) * | 2016-06-17 | 2017-12-21 | Fronthera U.S. Pharmaceuticals Llc | Hemoglobin modifier compounds and uses thereof |
| SG11201900344YA (en) * | 2016-07-15 | 2019-02-27 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| US20200087403A1 (en) * | 2017-03-15 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of thrombosis in patients suffering from a myeloproliferative neoplasm |
-
2019
- 2019-03-07 CA CA3092931A patent/CA3092931A1/en active Pending
- 2019-03-07 JP JP2020547136A patent/JP2021515027A/ja active Pending
- 2019-03-07 MX MX2020009305A patent/MX2020009305A/es unknown
- 2019-03-07 BR BR112020018135-8A patent/BR112020018135A2/pt not_active IP Right Cessation
- 2019-03-07 CN CN201980017343.XA patent/CN112041344A/zh active Pending
- 2019-03-07 CN CN202410168812.0A patent/CN118161607A/zh active Pending
- 2019-03-07 AU AU2019229885A patent/AU2019229885A1/en not_active Abandoned
- 2019-03-07 KR KR1020207025514A patent/KR20210003086A/ko not_active Withdrawn
- 2019-03-07 EP EP19715573.2A patent/EP3762424A1/en not_active Withdrawn
- 2019-03-07 WO PCT/IB2019/051859 patent/WO2019171326A1/en not_active Ceased
- 2019-03-07 US US16/977,126 patent/US20210002374A1/en not_active Abandoned
- 2019-03-07 RU RU2020132460A patent/RU2020132460A/ru unknown
-
2020
- 2020-08-25 IL IL276937A patent/IL276937A/en unknown
- 2020-09-04 CL CL2020002294A patent/CL2020002294A1/es unknown
-
2023
- 2023-06-07 US US18/330,844 patent/US20240190971A1/en not_active Abandoned
-
2024
- 2024-01-19 JP JP2024006797A patent/JP2024054143A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3092931A1 (en) | 2019-09-12 |
| WO2019171326A1 (en) | 2019-09-12 |
| IL276937A (en) | 2020-10-29 |
| EP3762424A1 (en) | 2021-01-13 |
| KR20210003086A (ko) | 2021-01-11 |
| BR112020018135A2 (pt) | 2020-12-22 |
| MX2020009305A (es) | 2020-11-24 |
| US20240190971A1 (en) | 2024-06-13 |
| RU2020132460A3 (es) | 2022-04-08 |
| JP2024054143A (ja) | 2024-04-16 |
| JP2021515027A (ja) | 2021-06-17 |
| CN112041344A (zh) | 2020-12-04 |
| AU2019229885A1 (en) | 2020-09-10 |
| US20210002374A1 (en) | 2021-01-07 |
| RU2020132460A (ru) | 2022-04-08 |
| CN118161607A (zh) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000187A (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
| CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
| CO2017012991A2 (es) | Agonistas de triazol del receptor apj | |
| CR20170600A (es) | Anticuerpos del factor x1 y métodos de uso | |
| CL2017001920A1 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
| MX2019009443A (es) | Metodos para tratar la influenza. | |
| CO2018014010A2 (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
| BR112018003985A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| CL2020002294A1 (es) | Uso de un anticuerpo anti–p–selectina | |
| PE20180556A1 (es) | Anticuerpos inhibidores via del factor tisular y usos de los mismos | |
| EA201992784A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| EA201992782A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| EA201992334A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| MX2018013517A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| EA201890723A1 (ru) | Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге | |
| EA201791614A1 (ru) | Производные индола в качестве ингибиторов репликации вирусов денге | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| AR112103A1 (es) | Compuestos para el tratamiento de tnbc | |
| MX2020009296A (es) | Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso. | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| EA202190057A1 (ru) | Солюбилизированные апиразы, способы и применение | |
| CO2019009000A2 (es) | Combinaciones farmacéuticas para tratar cáncer | |
| CL2022000790A1 (es) | Método para tratar vih con cabotegravir y rilpivirina | |
| CL2021000107A1 (es) | Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma |